Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2008 1
2018 3
2019 4
2022 1
2023 4
2024 3
2025 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

13 results

Results by year

Filters applied: . Clear all
Page 1
Effect on Survival of Androgen Deprivation Therapy Alone Compared to Androgen Deprivation Therapy Combined with Concurrent Radiation Therapy to the Prostate in Patients with Primary Bone Metastatic Prostate Cancer in a Prospective Randomised Clinical Trial: Data from the HORRAD Trial.
Boevé LMS, Hulshof MCCM, Vis AN, Zwinderman AH, Twisk JWR, Witjes WPJ, Delaere KPJ, Moorselaar RJAV, Verhagen PCMS, van Andel G. Boevé LMS, et al. Eur Urol. 2019 Mar;75(3):410-418. doi: 10.1016/j.eururo.2018.09.008. Epub 2018 Sep 25. Eur Urol. 2019. PMID: 30266309 Clinical Trial.
Using prostate-specific membrane antigen positron-emission tomography to guide prostate biopsies and stage men at high-risk of prostate cancer.
Bodar YJL, Boevé LMS, van Leeuwen PJ, Baars PC, Nieuwenhuijzen JA, van Haarst EP, Oddens JR, Donswijk ML, van Riel LAMJG, Scheltema MJ, Meijer D, Hendrikse NH, Oprea-Lager DE, Vis AN. Bodar YJL, et al. Among authors: boeve lms. BJU Int. 2023 Dec;132(6):705-712. doi: 10.1111/bju.16167. Epub 2023 Sep 13. BJU Int. 2023. PMID: 37620288
Prostate Cancer-related Events in Patients with Synchronous Metastatic Hormone-sensitive Prostate Cancer Treated with Androgen Deprivation Therapy with and Without Concurrent Radiation Therapy to the Prostate; Data from the HORRAD Trial.
Boevé LMS, Hulshof MCCM, Verhagen PCMS, Twisk JWR, Witjes WPJ, de Vries P, Jeroen A van Moorselaar R, Vis AN, van Andel G. Boevé LMS, et al. Eur Urol. 2024 Sep 19:S0302-2838(24)02593-4. doi: 10.1016/j.eururo.2024.08.035. Online ahead of print. Eur Urol. 2024. PMID: 39304427
A Comparison of Globally Applied Prognostic Risk Groups and the Prevalence of Metastatic Disease on Prostate-specific Membrane Antigen Positron Emission Tomography in Patients with Newly Diagnosed Prostate Cancer.
Luining WI, Boevé LMS, Hagens MJ, Meijer D, de Weijer T, Ettema RH, Knol RJJ, Roeleveld TA, Srbljin S, Weltings S, Koppes JCC, van Moorselaar RJA, van Leeuwen PJ, Cysouw MCF, Oprea-Lager DE, Vis AN. Luining WI, et al. Among authors: boeve lms. Eur Urol Oncol. 2024 Apr 30:S2588-9311(24)00097-X. doi: 10.1016/j.euo.2024.04.005. Online ahead of print. Eur Urol Oncol. 2024. PMID: 38693019 Free article.
The appropriateness of PSMA PET/CT in newly diagnosed unfavorable intermediate-risk prostate cancer patients-towards a tumor volume-based risk stratification.
Hagens MJ, Luining WI, Boevé LMS, Knol RJJ, Roeleveld TA, Srbljin S, Weltings S, Koppes JCC, Oprea-Lager DE, Vis AN, van Leeuwen PJ, van der Poel HG. Hagens MJ, et al. Among authors: boeve lms. Prostate Cancer Prostatic Dis. 2024 Sep 23. doi: 10.1038/s41391-024-00899-9. Online ahead of print. Prostate Cancer Prostatic Dis. 2024. PMID: 39313655
Reply to Fabiana Gregucci and Alba Fiorentino's Letter to the Editor re: Liselotte M.S. Boevé, Maarten C.C.M. Hulshof, André N. Vis, et al. Effect on Survival of Androgen Deprivation Therapy Alone Compared to Androgen Deprivation Therapy Combined with Concurrent Radiation Therapy to the Prostate in Patients with Primary Bone Metastatic Prostate Cancer in a Prospective Randomized Clinical Trial: Data from the HORRAD Trial. Eur Urol 2019;75:410-8.
Vis AN, Boevé LMS. Vis AN, et al. Among authors: boeve lms. Eur Urol. 2019 May;75(5):e131-e132. doi: 10.1016/j.eururo.2018.12.024. Epub 2019 Jan 4. Eur Urol. 2019. PMID: 30616950 No abstract available.
Reply to Herney Andrés García-Perdomo's Letter to the Editor re: Liselotte M.S. Boevé, Maarten C.C.M. Hulshof, André N. Vis, et al. Effect on Survival of Androgen Deprivation Therapy Alone Compared to Androgen Deprivation Therapy Combined with Concurrent Radiation Therapy to the Prostate in Patients with Primary Bone Metastatic Prostate Cancer in a Prospective Randomised Clinical Trial: Data from the HORRAD Trial. Eur Urol. 2019;75:410-8. High-volume Disease Has a Different Standard of Care: Is Local Treatment Really Beneficial in Low-volume Metastatic Prostate Cancer?
Boevé LMS, Vis AN. Boevé LMS, et al. Eur Urol. 2019 Apr;75(4):e101-e102. doi: 10.1016/j.eururo.2018.11.034. Epub 2018 Nov 30. Eur Urol. 2019. PMID: 30503181 No abstract available.
Reply to Ashwin Shinde, Richard Li, Arya Amini, and Scott Glaser's Letter to the Editor re: Liselotte M.S. Boevé, Maarten C.C.M. Hulshof, André N. Vis, et al. Effect on Survival of Androgen Deprivation Therapy Alone Compared to Androgen Deprivation Therapy Combined with Concurrent Radiation Therapy to the Prostate in Patients with Primary Bone Metastatic Prostate Cancer in a Prospective Randomised Clinical Trial: Data from the HORRAD Trial. Eur Urol 2019;75:410-8: Future Steps for Definitive Therapy in Metastatic Prostate Cancer: Lessons from the HORRAD TrialUntil Randomised Controlled Trials Prove Different, Treat the Patient, Not His Imaging Results.
Boevé LMS, Verhagen PCMS, Vis AN. Boevé LMS, et al. Eur Urol. 2019 Mar;75(3):e71-e72. doi: 10.1016/j.eururo.2018.11.007. Epub 2018 Nov 22. Eur Urol. 2019. PMID: 30471883 No abstract available.
13 results